These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 27272482)

  • 1. Sarcopenia/Muscle Mass is not a Prognostic Factor for Short- and Long-Term Outcome After Esophagectomy for Cancer.
    Grotenhuis BA; Shapiro J; van Adrichem S; de Vries M; Koek M; Wijnhoven BP; van Lanschot JJ
    World J Surg; 2016 Nov; 40(11):2698-2704. PubMed ID: 27272482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of sarcopenia in patients undergoing esophagectomy for superficial esophageal squamous cell carcinoma.
    Oguma J; Ozawa S; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
    Dis Esophagus; 2019 Jul; 32(7):. PubMed ID: 30809629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcopenia as a predictor of pulmonary complications after esophagectomy for thoracic esophageal cancer.
    Nishigori T; Okabe H; Tanaka E; Tsunoda S; Hisamori S; Sakai Y
    J Surg Oncol; 2016 May; 113(6):678-84. PubMed ID: 26936808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy: a comprehensive systematic review and meta-analysis.
    Deng HY; Zha P; Peng L; Hou L; Huang KL; Li XY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30496385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia is not associated with morbidity, mortality, or recurrence after esophagectomy for cancer.
    Siegal SR; Dolan JP; Dewey EN; Guimaraes AR; Tieu BH; Schipper PH; Hunter JG
    Am J Surg; 2018 May; 215(5):813-817. PubMed ID: 29310892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
    Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
    World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
    Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
    Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
    Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
    Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
    Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
    Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
    World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
    Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
    Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
    Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
    Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.
    Paireder M; Asari R; Kristo I; Rieder E; Tamandl D; Ba-Ssalamah A; Schoppmann SF
    Eur J Surg Oncol; 2017 Feb; 43(2):478-484. PubMed ID: 28024944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer.
    Tamandl D; Paireder M; Asari R; Baltzer PA; Schoppmann SF; Ba-Ssalamah A
    Eur Radiol; 2016 May; 26(5):1359-67. PubMed ID: 26334504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer.
    Kudou K; Saeki H; Nakashima Y; Edahiro K; Korehisa S; Taniguchi D; Tsutsumi R; Nishimura S; Nakaji Y; Akiyama S; Tajiri H; Nakanishi R; Kurashige J; Sugiyama M; Oki E; Maehara Y
    Ann Surg Oncol; 2017 Jul; 24(7):1804-1810. PubMed ID: 28224363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
    Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
    World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
    Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
    Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.